Literature DB >> 16133988

No indication for a defect in toll-like receptor signaling in patients with hyper-IgE syndrome.

E D Renner1, I Pawlita, F Hoffmann, V Hornung, D Hartl, M Albert, A Jansson, S Endres, G Hartmann, B H Belohradsky, S Rothenfusser.   

Abstract

Hyper-IgE syndrome is a rare primary immunodeficiency of unknown etiology characterized by recurrent infections of the skin and respiratory system, chronic eczema, elevated total serum IgE, and a variety of associated skeletal symptoms. Recent reports about susceptibility to pyogenic bacterial infections and high IgE levels in patients and animals with defects in toll-like receptor (TLR) signaling pathways prompted us to search for TLR signaling defects as an underlying cause of hyper-IgE syndrome. Blood samples from six patients with hyper-IgE syndrome were analyzed for serum cytokine levels, intracellular cytokine production in T cells after stimulation with PMA/ionomycin, and cytokine production from peripheral blood mononuclear cells stimulated by TLR ligands and bacterial products including LPS (TLR4), peptidoglycan (TLR2), PolyIC (TLR3), R848 (TLR7/8), CpG-A, and CpG-B (TLR9), zymosan and heat killed Listeria monocytogenes. All results were compared to data from healthy controls. A reduction in IFN-gamma, IL-2, and TNF-alpha producing T cells after PMA stimulation suggested a reduced inflammatory T cell response in patients with hyper-IgE syndrome. Increased serum levels of IL-5 indicated a concomitant Th2 shift. However, normal production of cytokines (TNF-alpha, IL-6, IL-10, IFN-alpha, IP-10) and upregulation of CD86 on B cells and monocytes after TLR stimulation made a defect in TLR signaling pathways highly unlikely. In summary, our data confirmed an imbalance in T cell responses of patients with hyper-IgE syndrome as previously described but showed no indication for an underlying defect in toll-like receptor signaling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16133988     DOI: 10.1007/s10875-005-4183-2

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  35 in total

1.  Toll-like receptors control activation of adaptive immune responses.

Authors:  M Schnare; G M Barton; A C Holt; K Takeda; S Akira; R Medzhitov
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

2.  Bone marrow transplantation does not correct the hyper IgE syndrome.

Authors:  A R Gennery; T J Flood; M Abinun; A J Cant
Journal:  Bone Marrow Transplant       Date:  2000-06       Impact factor: 5.483

3.  A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection.

Authors:  E Lorenz; J P Mira; K L Cornish; N C Arbour; D A Schwartz
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

4.  Abnormal expression of CD54 in mixed reactions of mononuclear cells from hyper-IgE syndrome patients.

Authors:  Adriano M Martínez; Carlos J Montoya; María T Rugeles; José L Franco; Pablo J Patiño
Journal:  Mem Inst Oswaldo Cruz       Date:  2004-06-24       Impact factor: 2.743

Review 5.  Eosinophils and atopic dermatitis.

Authors:  D Simon; L R Braathen; H-U Simon
Journal:  Allergy       Date:  2004-06       Impact factor: 13.146

Review 6.  Toll-like receptors in the pathogenesis of human disease.

Authors:  Donald N Cook; David S Pisetsky; David A Schwartz
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

7.  CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro.

Authors:  Simon Rothenfusser; Veit Hornung; Maha Ayyoub; Stefanie Britsch; Andreas Towarowski; Anne Krug; Anja Sarris; Norbert Lubenow; Daniel Speiser; Stefan Endres; Gunther Hartmann
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

8.  Cytokine imbalance in hyper-IgE syndrome: reduced expression of transforming growth factor beta and interferon gamma genes in circulating activated T cells.

Authors:  Shouichi Ohga; Akihiko Nomura; Kenji Ihara; Yasushi Takahata; Naohiro Suga; Hideki Akeda; Rumiko Shibata; Jun Okamura; Naoko Kinukawa; Toshiro Hara
Journal:  Br J Haematol       Date:  2003-04       Impact factor: 6.998

9.  Two inhibitors of neutrophil chemotaxis are produced by hyperimmunoglobulin E recurrent infection syndrome mononuclear cells exposed to heat-killed staphylococci.

Authors:  H Donabedian; J I Gallin
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

10.  Increased expression of interleukin-13 but not interleukin-4 in CD4+ cells from patients with the hyper-IgE syndrome.

Authors:  K O Gudmundsson; O E Sigurjonsson; S Gudmundsson; D Goldblatt; C M R Weemaes; A Haraldsson
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

View more
  5 in total

Review 1.  Toll-like receptor signaling in primary immune deficiencies.

Authors:  Paul J Maglione; Noa Simchoni; Charlotte Cunningham-Rundles
Journal:  Ann N Y Acad Sci       Date:  2015-04-30       Impact factor: 5.691

2.  TNF overproduction impairs epithelial staphylococcal response in hyper IgE syndrome.

Authors:  Ian A Myles; Erik D Anderson; Noah J Earland; Kol A Zarember; Inka Sastalla; Kelli W Williams; Portia Gough; Ian N Moore; Sundar Ganesan; Cedar J Fowler; Arian Laurence; Mary Garofalo; Douglas B Kuhns; Mark D Kieh; Arhum Saleem; Pamela A Welch; Dirk A Darnell; John I Gallin; Alexandra F Freeman; Steven M Holland; Sandip K Datta
Journal:  J Clin Invest       Date:  2018-07-23       Impact factor: 14.808

3.  Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome.

Authors:  Ellen D Renner; Stacey Rylaarsdam; Stephanie Anover-Sombke; Anita L Rack; Janine Reichenbach; John C Carey; Qili Zhu; Annette F Jansson; Julia Barboza; Lena F Schimke; Mark F Leppert; Melissa M Getz; Reinhard A Seger; Harry R Hill; Bernd H Belohradsky; Troy R Torgerson; Hans D Ochs
Journal:  J Allergy Clin Immunol       Date:  2008-07       Impact factor: 10.793

Review 4.  Staphylococcus aureus and Hyper-IgE Syndrome.

Authors:  Bonggoo Park; George Y Liu
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

5.  Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome.

Authors:  Yoshiyuki Minegishi; Masako Saito; Masayuki Nagasawa; Hidetoshi Takada; Toshiro Hara; Shigeru Tsuchiya; Kazunaga Agematsu; Masafumi Yamada; Nobuaki Kawamura; Tadashi Ariga; Ikuya Tsuge; Hajime Karasuyama
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.